- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04343573
Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors
A Phase II Randomized Study Assessing the Efficacy of Proton Craniospinal Irradiation (CSI) vs Involved-field Photon Radiation Therapy for Leptomeningeal Metastases From Solid Tumor Malignancies
The investigators are doing this study to find out whether proton craniospinal radiation therapy (proton CSI) or partial photon radiation therapy is more effective at preventing leptomeningeal metastasis from worsening. The proton CSI targets the entire space containing the CSF, brain, and spinal fluid. The partial photon radiation therapy treats only areas where the patient is having symptoms, such as the entire brain or part of the spine. The investigators also want to find out if proton CSI improves the symptoms patients may be experiencing because of the leptomeningeal metastasis. In addition, the investigators will compare the side effects of proton CSI and partial photon therapy.
Patients undergoing proton beam RT will receive their treatment at the New York Proton Center in New York, NY. As part of the New York Proton Consortium, MSK has contracted for its faculty to treat patients at the New York Proton Center. If it is unfeasible for patients to get treated at NYPC, patients will have the decision to get treated at ProCure in Summerset, NJ.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth (Limitedl protocol activities)
-
Montvale, New Jersey, United States, 07645
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Commack (Limited protocol activities)
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, United States, 11553
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient with solid tumor malignancy with leptomeningeal metastases established radiographically and/or through CSF cytology
- Patients who are candidates for radiation therapy for the treatment of leptomeningeal metastases
- Patients of all ages
- KPS ≥ 60 for participants ≥ 16 years old, and Lansky ≥ 60 for participants < 16 years old
- For adult patient, the patient/ legally authorized representative is able to provide informed consent. For pediatric patient, a parent is able to provide informed consent.
Adequate bone marrow function:
- Hemoglobin > 8g/dL
- Absolute neutrophil count >1,000/mm
- Platelet count > 100,000/mm
- Female subjects must either be of non-reproductive potential (i.e. pediatric patients, OR postmenopausal by history [≥ 60 years old, or with no menses for >1 year without an alternative medical cause], OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment.
- Patient at reproductive potential must agree to practice an effective contraceptive method.
Exclusion Criteria:
- Patient with multiple, serious major neurologic deficits per physician/investigator assessment including encephalopathy
- Patient with extensive systemic disease and without reasonable systemic treatment options
- Patient who is unable to undergo MRI brain and spine with gadolinium contrast
- Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Proton CSI Followed by Standard of Care (NSCLC & Breast)
Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
|
Proton CSI (30Gy [RBE] in 10 fractions)
All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT.
The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available.
Patients will also complete self-report mood and fatigue scales at each of the same time points.
This testing will only be done at MSKCC.
Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments.
Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression.
Only one set needs to be completed.
Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available.
Questionnaires will be completed via mail, in-person, or online (MSK Engage).
Other Names:
|
Experimental: Standard of Care
Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
|
All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT.
The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available.
Patients will also complete self-report mood and fatigue scales at each of the same time points.
This testing will only be done at MSKCC.
Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments.
Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression.
Only one set needs to be completed.
Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available.
Questionnaires will be completed via mail, in-person, or online (MSK Engage).
Other Names:
Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
|
Other: Proton CSI Followed by Standard of Care (Other Solid Tumors)
(Exploratory arm) Patients with solid tumor malignancies other than NSCLC or breast cancer will be enrolled to the exploratory proton CSI arm (Arm C) and will not undergo randomization.
Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
|
Proton CSI (30Gy [RBE] in 10 fractions)
All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT.
The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available.
Patients will also complete self-report mood and fatigue scales at each of the same time points.
This testing will only be done at MSKCC.
Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments.
Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression.
Only one set needs to be completed.
Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available.
Questionnaires will be completed via mail, in-person, or online (MSK Engage).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CNS progression free survival
Time Frame: 2 years
|
For Arm A and Arm B, which will be defined as the duration of time from the date of randomization to the time of progression of disease or death, whichever occurs first.
The baseline imaging study will be the diagnostic imaging obtained at study entry.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival (OS) (Arm A and Arm B)
Time Frame: 2 years
|
will be included in an analysis of overall survival, defined as time from randomization to death.
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Divya Yerramilli, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leptomeningeal Metastases
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnLeptomeningeal Metastases
-
Memorial Sloan Kettering Cancer CenterCenter for Experimental Therapeutics; F.M. KIRBY FOUNDATIONRecruitingLeptomeningeal MetastasesUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedLeptomeningeal MetastasesUnited States
-
H. Lee Moffitt Cancer Center and Research InstitutePfizerActive, not recruitingLeptomeningeal Metastases | Leptomeningeal DiseaseUnited States
-
West China HospitalNot yet recruitingNSCLC Associated With Leptomeningeal Metastases
-
The First Hospital of Jilin UniversityThe Second Hospital of Hebei Medical University; Second Affiliated Hospital... and other collaboratorsActive, not recruiting
-
The First Hospital of Jilin UniversityCompletedLeptomeningeal MetastasesChina
-
Centre Oscar LambretCompletedBreast Cancer | Leptomeningeal MetastasesFrance
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Biocept, Inc.ICON plcTerminatedBreast Cancer | Non-Small Cell Lung Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis | Leptomeningeal NeoplasmsUnited States
Clinical Trials on Proton Craniospinal Irradiation (CSI)
-
Memorial Sloan Kettering Cancer CenterCompletedLeptomeningeal MetastasesUnited States
-
Tata Memorial CentreRecruitingMedulloblastoma, WNT-activatedIndia
-
St. Jude Children's Research HospitalActive, not recruitingEpendymomaUnited States, Canada
-
University Hospital HeidelbergRecruiting
-
Massachusetts General HospitalM.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Pennsylvania and other collaboratorsCompletedLiver CancerUnited States
-
University of CincinnatiWithdrawn
-
Centre Francois BaclesseRégion NormandieRecruitingMeningioma | Radiation ToxicityFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingInvasive Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma | Ductal Breast Carcinoma In Situ and other conditionsUnited States
-
University of California, DavisUniversity of California, San FranciscoCompletedExudative Age-related Macular DegenerationUnited States
-
University Hospital MuensterHannover Medical School; Deutsche Kinderkrebsstiftung; Gesellschaft fur Padiatrische...UnknownIntracranial Germ Cell TumorsGermany